<SEC-DOCUMENT>0001744329-24-000005.txt : 20240917
<SEC-HEADER>0001744329-24-000005.hdr.sgml : 20240917
<ACCEPTANCE-DATETIME>20240917134910
ACCESSION NUMBER:		0001744329-24-000005
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20240917
DATE AS OF CHANGE:		20240917

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-39373
		FILM NUMBER:		241303527

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SRK FUND I, LP
		CENTRAL INDEX KEY:			0001744329
		ORGANIZATION NAME:           	
		IRS NUMBER:				824121679
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		206 SOUTH AVE
		STREET 2:		STE 8
		CITY:			MEDIA
		STATE:			PA
		ZIP:			19063
		BUSINESS PHONE:		6104241017

	MAIL ADDRESS:	
		STREET 1:		206 SOUTH AVE
		STREET 2:		STE 8
		CITY:			MEDIA
		STATE:			PA
		ZIP:			19063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SRK Fund I, LP.
		DATE OF NAME CHANGE:	20180621
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <previousAccessionNumber>0001744329-24-000003</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001744329</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>1</amendmentNo>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <dateOfEvent>09/17/2024</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0000811641</issuerCIK>
        <issuerCUSIP>452525306</issuerCUSIP>
        <issuerName>IMMUCELL CORP /DE/</issuerName>
        <address>
          <com:street1>56 EVERGREEN DR</com:street1>
          <com:street2>56 EVERGREEN DR</com:street2>
          <com:city>PORTLAND</com:city>
          <com:stateOrCountry>ME</com:stateOrCountry>
          <com:zipCode>04103</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>SRK CAPITAL, LLC</personName>
          <personPhoneNum>(610) 424-1017</personPhoneNum>
          <personAddress>
            <com:street1>206 South Avenue</com:street1>
            <com:street2>Ste 8</com:street2>
            <com:city>Media</com:city>
            <com:stateOrCountry>PA</com:stateOrCountry>
            <com:zipCode>19063</com:zipCode>
          </personAddress>
        </notificationInfo>
        <notificationInfo>
          <personName>SEAN KIRKWOOD</personName>
          <personPhoneNum>(610) 424-1017</personPhoneNum>
          <personAddress>
            <com:street1>206 South Avenue</com:street1>
            <com:street2>Ste 8</com:street2>
            <com:city>Media</com:city>
            <com:stateOrCountry>PA</com:stateOrCountry>
            <com:zipCode>19063</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001744329</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>SRK FUND I, LP</reportingPersonName>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <sharedVotingPower>502258.00</sharedVotingPower>
        <sharedDispositivePower>502258.00</sharedDispositivePower>
        <aggregateAmountOwned>502258.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>6.4</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>Percentage calculated based on 7,833,080 shares of common stock, par value $0.10 per share, outstanding as of August 2, 2024, as reported in the Form 10-Q for the fiscal quarter ended June 30, 2024 of ImmuCell Corporation.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>SRK Capital, LLC</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>PA</citizenshipOrOrganization>
        <sharedVotingPower>502258.00</sharedVotingPower>
        <sharedDispositivePower>502258.00</sharedDispositivePower>
        <aggregateAmountOwned>502258.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>6.4</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
        <commentContent>Percentage calculated based on 7,833,080 shares of common stock, par value $0.10 per share, outstanding as of August 2, 2024, as reported in the Form 10-Q for the fiscal quarter ended June 30, 2024 of ImmuCell Corporation.</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonNoCIK>Y</reportingPersonNoCIK>
        <reportingPersonName>Sean Kirkwood</reportingPersonName>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <sharedVotingPower>502258.00</sharedVotingPower>
        <sharedDispositivePower>502258.00</sharedDispositivePower>
        <aggregateAmountOwned>502258.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>6.4</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
        <commentContent>Percentage calculated based on 7,833,080 shares of common stock, par value $0.10 per share, outstanding as of August 2, 2024, as reported in the Form 10-Q for the fiscal quarter ended June 30, 2024 of ImmuCell Corporation.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock</securityTitle>
        <issuerName>IMMUCELL CORP /DE/</issuerName>
        <issuerPrincipalAddress>
          <com:street1>56 EVERGREEN DR</com:street1>
          <com:street2>56 EVERGREEN DR</com:street2>
          <com:city>PORTLAND</com:city>
          <com:stateOrCountry>ME</com:stateOrCountry>
          <com:zipCode>04103</com:zipCode>
        </issuerPrincipalAddress>
      </item1>
      <item3>
        <fundsSource>The shares purchased by SRK Fund were purchased with working capital (which may, at any given time, include margin loans made by brokerage firms in the ordinary course of business) in open market purchases, except as otherwise noted. The aggregate purchase price of the 502,258 Shares beneficially owned by SRK Fund is approximately $2,430,957.</fundsSource>
      </item3>
      <item5>
        <percentageOfClassSecurities>As of the date hereof, SRK Fund beneficially owned 502,258 Shares. Representing approximately 6.4% of the outstanding shares.

SRK Capital, as the general partner of SRK Fund, may be deemed the beneficial owner of the 502,258 Shares owned by SRK Fund. Representing approximately 6.4% of the outstanding shares.

Mr. Kirkwood,  as the sole owner, member, and manager of SRK Capital, may be deemed the beneficial owner of the 502,258 Shares owned by SRK Fund. Representing approximately 6.4% of the outstanding shares.</percentageOfClassSecurities>
        <numberOfShares>SRK Fund:
1. Sole power to vote or direct vote: 0
2. Shared power to vote or direct vote: 502,258
3. Sole power to dispose or direct the disposition: 0
4. Shared power to dispose or direct the disposition: 502,258

SRK Capital:
1. Sole power to vote or direct vote: 0
2. Shared power to vote or direct vote: 502,258
3. Sole power to dispose or direct the disposition: 0
4. Shared power to dispose or direct the disposition: 502,258

Mr. Kirkwood:
1. Sole power to vote or direct vote: 0
2. Shared power to vote or direct vote: 502,258
3. Sole power to dispose or direct the disposition: 0
4. Shared power to dispose or direct the disposition: 502,258</numberOfShares>
        <transactionDesc>This Schedule sets forth information with respect to each purchase and sale of shares of Common Stock which were effectuated by the Reporting Person within the past sixty (60) days. All transactions were effectuated in the open market through a broker. Where the price reported in the column titled "Price Per Share ($)" is a weighted average price. The Reporting Persons will undertake to provide to the staff of the SEC, upon request, full information regarding the number of shares of Common Stock sold or purchased at each separate price.

Trade Date	       Shares Purchased	Price Per Share ($)
7/19/2024	              3,900	                        4.19
7/25/2024	              7,200             	        4.08
8/02/2024	            22,900                  	3.99
8/05/2024	              5,622           	        3.72
8/06/2024	              2,446            	        3.89
8/08/2024	              5,701 	                3.70
8/13/2024	                 100             	        3.82
8/22/2024	              4,900           	        3.55
8/27/2024                     6,810                         3.85
8/29/2024                   16,601                         3.80
9/10/2024                     1,000                         3.85
9/17/2024                   12,000                         3.48</transactionDesc>
        <listOfShareholders>To the knowledge of any of the Reporting Persons, no other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares reported in this Item 5.</listOfShareholders>
        <date5PercentOwnership>Not applicable.</date5PercentOwnership>
      </item5>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>SRK FUND I, LP</signatureReportingPerson>
        <signatureDetails>
          <signature>SRK Capital, LLC</signature>
          <title>general partner</title>
          <date>09/17/2024</date>
        </signatureDetails>
        <signatureDetails>
          <signature>Sean Kirkwood</signature>
          <title>Authorized Signatory</title>
          <date>09/17/2024</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>SRK Capital, LLC</signatureReportingPerson>
        <signatureDetails>
          <signature>Sean Kirkwood</signature>
          <title>manager</title>
          <date>09/17/2024</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Sean Kirkwood</signatureReportingPerson>
        <signatureDetails>
          <signature>Sean Kirkwood</signature>
          <title>Sean Kirkwood</title>
          <date>09/17/2024</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
